Company Overview of Andrx Corporation
Andrx Corporation is a holding company. The company, through its subsidiaries, develops, manufactures, commercializes, and distributes generic versions of controlled-release pharmaceuticals, oral contraceptives, and generic versions of immediate-release products. It also develops and commercializes brand name pharmaceuticals; and distributes primarily generics that are commercialized by others and its own products. In addition, the company offers contract services such as development and manufacture of pharmaceutical products including combination products and controlled-release formulations for other pharmaceutical companies; and contract research and development services. It also markets g...
4955 Orange Drive
Davie, FL 33314
Founded in 1992
Key Executives for Andrx Corporation
Chief Information Officer, Senior Vice President and Head of Project Management Office
Executive Vice President of Commercial Development
Compensation as of Fiscal Year 2016.
Andrx Corporation Key Developments
Cipher Pharmaceuticals Inc., Ranbaxy Pharmaceuticals, Inc. and Galephar Pharmaceutical Research, Inc. Enters into Settlement Agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc
Oct 5 15
Cipher Pharmaceuticals Inc. along with its partners, Ranbaxy Pharmaceuticals, Inc. and Galephar Pharmaceutical Research, Inc. have entered into a settlement agreement with Actavis Laboratories F1, Inc., Andrx Corp., Actavis, Inc. and Actavis Pharma, Inc. that dismisses the patent litigation suit relating to Actavis' Abbreviated New Drug Application (ANDA) for a generic version of Absorica (isotretinoin capsules). As part of the settlement agreement, Cipher, Ranbaxy and Galephar have entered into a non-exclusive license agreement with Actavis under which Actavis may begin selling its generic version of Absorica in the U.S. on December 27, 2020 (approximately nine months prior to the expiration of the patents in September 2021) or earlier under certain circumstances. The settlement agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Orexigen Therapeutics, Inc. and Takeda Pharmaceuticals File Lawsuit against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc. and Actavis Inc. For Infringement of Contrave Patents
Jun 5 15
Orexigen Therapeutics, Inc. announced that it and its North American partner, Takeda Pharmaceuticals, have filed a lawsuit in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell generic versions of the currently approved doses of Contrave (naltrexone HCl /bupropion HCl extended release) tablets prior to the expiration of U.S. Patents listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. Takeda and Orexigen filed the lawsuit on the basis that Actavis' proposed generic products infringe each of these patents.
Galena Biopharma's Partner Orexo Files Patent Infringement Suit Against Actavis Laboratories, Andrx Corporation, Actavis, Inc. and Actavis Pharma
Feb 5 15
Galena Biopharma (GALE) announced that its partner Orexo has filed a patent infringement lawsuit in United States District Court for the District of New Jersey, against Actavis Laboratories, Andrx Corporation, Actavis Inc. (ACT) and Actavis Pharma for seeking to market a generic version of its Abstral drug. The lawsuit was filed in response to an Abbreviated New Drug Application filed by Actavis. In its application, Actavis seeks to market and sell generic versions of Abstral sublingual tablets in the U.S. prior to the expiration of Orexo's U.S. patents.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|